Nastech Pharmaceuticals - Worst Pharma Stocks of 2007

Company: Nastech Pharmaceuticals 
Starting stock price: $14.68
Ending stock price: $3.80
Percent Change: -74.11%

Details: Early in 2007 Merck announced that a preliminary study of Nastech's PYY3-36 anti-obesity spray demonstrated no effect and was pulling out of a collaboration to develop the therapy. Then, in November, Nastech took another serious hit after Procter & Gamble pulled out of its efforts on an osteoporosis nasal spray treatment. The company has since announced plans to restructure, including plans to lay off some of its 197 workers.

More News:
Nastech spins off RNAi unit, restructures. Report
Nastech shares wilt after P&G returns drug rights. Report
Nastech to push ahead with obesity spray trial. Report
Nastech hit on missed payment. Report

Nastech Pharmaceuticals - Worst Pharma Stocks of 2007
Read more on

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.